New York 2025-2026 Regular Session

New York Assembly Bill A03283

Introduced
1/27/25  
Refer
1/27/25  
Refer
1/7/26  
Report Pass
3/17/26  
Engrossed
3/23/26  

Caption

Requires gene synthesis providers and manufacturers of gene synthesis equipment to operate in accordance with rules and regulations issued by the department of health, including identifying potentially dangerous sequences and maintaining certain records.

Summary

Bill A03283, known as the 'Bioterrorism Prevention Act', aims to regulate the operation of gene synthesis providers and manufacturers of gene synthesis equipment in New York State. The bill mandates that these entities adhere to the protocols established by the International Gene Synthesis Consortium, particularly focusing on the identification of potentially dangerous genetic sequences and the maintenance of specific records. This regulation is intended to enhance public health safety and prevent the misuse of gene synthesis technology.

Impact

The passage of this bill will amend the public health law in New York by introducing new operational standards for gene synthesis providers and manufacturers. It will ensure that these entities comply with international safety protocols, thereby potentially reducing the risk of bioterrorism and other public health threats associated with genetic engineering. This law will also create a framework for oversight by the Department of Health, which may lead to increased accountability and monitoring of gene synthesis activities in the state.

Sentiment

The sentiment surrounding Bill A03283 appears to be largely positive, as evidenced by its favorable passage through the Assembly Health Committee with a vote of 25 to 1, followed by a unanimous final passage vote of 139 to 0 on the Assembly floor. This indicates strong bipartisan support for the bill, reflecting a shared concern for public health and safety in the context of advancing genetic technologies.

Contention

While the bill has garnered significant support, there may be concerns from stakeholders in the biotechnology sector regarding the potential regulatory burden imposed by these new requirements. Some may argue that stringent regulations could stifle innovation or impose excessive operational costs. However, specific points of contention were not detailed in the available committee discussions or voting records.

Companion Bills

NY S09279

Same As Requires gene synthesis providers and manufacturers of gene synthesis equipment to operate in accordance with rules and regulations issued by the department of health, including identifying potentially dangerous sequences and maintaining certain records.

Previously Filed As

NY S09279

Requires gene synthesis providers and manufacturers of gene synthesis equipment to operate in accordance with rules and regulations issued by the department of health, including identifying potentially dangerous sequences and maintaining certain records.

NY AB1864

An act to add Chapter 1.5 (commencing with Section 24200) to Division 20 of the Health and Safety Code, relating to gene synthesis.

NY A08314

Requires the department of health to enter into a contract with an entity experienced in maintaining genealogical research databases for the digitalization and indexing of certain vital records.

NY S07782

Requires the department of health to enter into a contract with an entity experienced in maintaining genealogical research databases for the digitalization and indexing of certain vital records.

NY S09200

Requires the department of health to enter into a contract with an entity experienced in maintaining genealogical research databases for the digitalization and indexing of certain vital records.

NY HB685

A BILL to amend the Code of Virginia by adding sections numbered 32.1-127.1:06 and 38.2-3407.15:9, relating to genetic sequencing; organ transplants; use of foreign genetic sequencing or genetic sequencer operational and research software; foreign storage of genetic sequencing data; health insurance coverage for certain foreign organ transplants; civil penalty.

NY SB234

Prohibiting the use of genetic sequencers or operational software used for genetic analysis that is produced in a foreign adversary.

NY SB311

To Create The End Organ And Genomic Harvesting Act; To Prohibit Coverage Of Certain Human Organ Transplant Or Post-transplant Care; And To Prohibit Certain Genetic Sequencers And Genetic Analysis Technologies.

NY A09136

Requires the owner or operator of a new data center to submit to the Public Service Commission a thermal energy network feasibility assessment that identifies potential off-site thermal loads within one mile of the facility; requires that new data centers be designed, constructed, and operated to capture and reuse waste heat generated by computing equipment through a thermal energy network.

NY HB49

Generally revise laws related to synthetic cannabinoids

Similar Bills

CA AB1864

Gene synthesis equipment manufacturers and providers.

NY S09279

Requires gene synthesis providers and manufacturers of gene synthesis equipment to operate in accordance with rules and regulations issued by the department of health, including identifying potentially dangerous sequences and maintaining certain records.

MN HF3452

Kratom classified as a Schedule II controlled substance.

MN SF3711

Kratom classification as a Schedule II controlled substance

LA SB154

Criminalizes the possession or distribution of kratom. (8/1/25)

NJ S322

Establishes tianeptine as Schedule II controlled dangerous substance.

NJ S2275

Bans carcinogens, reproductive toxicants, flame resistant chemicals, and volatile organic compounds from certain hair products.

NJ A2244

Bans carcinogens, reproductive toxicants, flame resistant chemicals, and volatile organic compounds from certain hair products.